After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.
Anavex announced new data from their phase 2b/3 Alzheimer's trial, which was presented at the CTAD 2024 conference. Read why ...
It also rejected another similar drug donanemab that had shown promise in suppressing symptoms of Alzheimer's. Both the ...
1d
When Frank Littleford was diagnosed with cancer, there was an immediate action plan. But his Alzheimer’s diagnosis was a ...
An Alzheimer's treatment, lecanemab, was found to triple the risk of death within a year, compared with dementia sufferers ...
GP Dr Adam has revealed the ways of guaranteeing a 'perfect' appointment when heading to the general practitioner, warning of ...
Shares of Disc Medicine Inc. (NASDAQ:IRON) were trading at $56.94, up $9.81, or 20%, after the firm disclosed positive feedback from its end-of-phase II meeting with the FDA, supporting the regulatory ...
New treatments for Alzheimer disease don’t reverse cognitive symptoms, but they do significantly slow progression. Evidence suggests that earlier treatment is most effective.
In a small early trial using a transcranial magnetic stimulation procedure, scientists were able to target a key brain ...
The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness ...
Young people are also at the heart of the Telegraph Christmas Charity Appeal 2024. Today and every day, seven young people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback